Intercell 3Q 2008: business combinations.

On 5 Aug 2008, Intercell AG completed the acquisition of 100% of the shares of Iomai Corp. Iomai is engaged in the discovery and development of novel vaccines and immune system stimulants, delivered via needle-free patch technology (transcutaneous immunization). Iomai was consolidated from 1 Aug 2008 onwards. The acquisition was accomplished through a stock-for-stock exchange of 1,442,819 newly issued Intercell shares (representing approximately 3.1% of Intercell's total outstanding shares after the acquisition) at an issue price of EUR 31.11/share, totalling a fair value of EUR 44.9 M for approximately 40.4% of Iomai's outstanding shares at closing, and a cash consideration …